- Aptorum Group Limited reported a **significantly reduced net loss** of **$(441,780)** for the six months ended June 30, 2025, compared to **$(2,643,796)** for the same period in 2024, primarily driven by a substantial decrease in research and development expenses.  **[1734005_0001213900-25-096129_ea025636201ex99-1_aptorum.htm:1]** **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:5]** **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:7]** 
- The company entered into an **Agreement and Plan of Merger with DiamiR Biosciences Corp.** on July 14, 2025, with DiamiR stockholders expected to own approximately **70%** and existing Aptorum shareholders **30%** of the combined company, and the merger is anticipated to close in the **fourth quarter 2025**.  **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:1]** **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:4]** **[1734005_0001213900-25-096129_ea025636201ex99-1_aptorum.htm:15]** 
- Management has determined that conditions, including a net loss of **$449,295**, working capital of **$1,998,298**, and an accumulated deficit of **$72,871,308** as of June 30, 2025, raise **substantial doubt about the Company's ability to continue as a going concern** within one year.  **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:3]** **[1734005_0001213900-25-096129_ea025636201ex99-2_aptorum.htm:7]**

Aptorum Group (APM)